SBBio Forges Vaccine Deal With Cantab
SmithKline Beecham Biologicals will work with Cantab on the development and marketing of the latter's TA-GW vaccine for genital warts. The deal is worth up to L24 million ($37.2 million) in license and milestone payments to Cantab, excluding royalties.
TA-GW is Cantab's lead product in its human papillomavirus program, and is currently in Phase II trials. The product may be useful both as a therapy and for prophylaxis of the condition, according to Cantab. Two other products in development at the company are TA-HPV, an immunotherapeutic for cervical cancer which is also in Phase II, and TA-CIN for precancerous cervical lesions, which is in preclinical development.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze